Top links
Access the Leniency Programme
Notify merger
Report anticompetitive practices
PT
Back to home
Main navigation
Open menu
ABOUT AdC
Expand submenu
Mission and Goals
Organization
Expand submenu
Careers
Procurement
Key Data
International Cooperation
Domestic Cooperation
COMPETITION
Expand submenu
The Benefits of Competition
Expand submenu
Leniency Programme
Anticompetitive Practices
Expand submenu
Abusive Practices
Collusive Practices
Merger Control
Expand submenu
Prior Assessment Procedure
Recommendations and Reports
CASES AND LEGISLATION
Expand submenu
Cases
STEP
Legislation
Public consultations
NEWS AND PUBLICATIONS
Expand submenu
News, press releases and speeches
Events
AdC Multimedia
C&R Journal and articles
AdC Competition Policy Award
Competition Library
Search
Search
Breadcrumb
PesquisAdC
Ccent/2019/31
Case details
Print
Merger control
Case reference
Ccent/2019/31 - Chiesi / Ativos Raxone
Acquired
Assets Raxone
Description
Approved medicine for the treatment of Leber Hereditary Optic Neuropathy.
Acquiring
CHIESI FARMACEUTICI, S.p.A.
Description
Company active in the pharmaceutical sector.
Sector
Health & Pharmaceutical
Activity (NACE)
Q86 - Human health activities
Applicable legislation
Art. 37(1)(a) (Law 19)
Notification thresholds
Market Share threshold
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description
The notified concentration consists of the acquisition of sole control over Ativos Raxone by Chiesi
Timeline
2019-07-12
2019-06-28
Click here to see your activities